Printer Friendly

ISIS ACQUIRES RIGHTS TO MULTIDRUG RESISTANCE PROTEIN

 CARLSBAD, Calif., June 25 /PRNewswire/ -- Isis Pharmaceuticals Inc. (NASDAQ: ISIP) today announced the signing of a license and research agreement with investigators at Queen's University in Kingston, Canada, granting Isis exclusive worldwide rights to develop and market oligonucleotide therapeutics targeting a novel multidrug resistance protein (MRP). Isis and the Queen's group will be working to discover these therapeutic compounds in a multiyear collaborative research program. The Queen's group -- the first team to both isolate and characterize the gene that produces MRP -- has filed a patent on the MRP gene sequence and related discoveries.
 Up to 90 percent of small cell lung cancer patients initially respond to chemotherapy; however, two-year survival rates are less than 10 percent because of relapse to drug-resistant disease. Production of MRP is believed to be responsible for the resistance of small cell lung cancers to chemotherapy treatment. MRP production is also thought to be the basis for inherent drug resistance of non-small cell lung cancers.
 The Queen's research group, headed by Drs. Susan Cole and Roger Deeley, was the first to publish data describing the isolation and characterization of the gene that produces MRP in the Dec. 4, 1992, issue of Science. Since its initial publication, the Queen's research team has been carrying out gene transfer experiments to demonstrate the causal relationship of MRP with chemotherapy resistance.
 Isis plans to use its antisense technology to develop drugs to block the synthesis of MRP and its proprietary oligonucleotide combinatorial strategy to develop drugs that interfere with MRP function.
 Isis Pharmaceuticals Inc., based in northern San Diego County, is engaged in the discovery and development of novel oligonucleotide-based human therapeutic compounds. Isis has a broad oligonucleotide research program and multiple compounds in preclinical development. The company's first oligonucleotide-based drug, ISIS 2105, is in pivotal Phase II clinical trials.
 -0- 6/25/93
 /CONTACT: Jacqueline G. Siegel, Ph.D., of Isis Pharmaceuticals, 619-931-9200; or Lorraine Ruff of Stoorza Ziegaus & Metzger, 619-236-1332, for Isis Pharmaceuticals/
 (ISIP)


CO: Isis Pharmaceuticals Inc. ST: California IN: MTC SU: LIC

JL-MF -- SD001 -- 5627 06/25/93 09:45 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 25, 1993
Words:345
Previous Article:CENTRAL PENNSYLVANIA FINANCIAL CORP. DECLARES DIVIDEND
Next Article:ALLEN R. GLASSBURN TO BE ELECTED PRESIDENT OF KINGSPORT POWER COMPANY
Topics:


Related Articles
VERTEX PHARMACEUTICALS EXPANDS CLINICAL PROGRAM IN CANCER MULTIDRUG RESISTANCE
Vertex Granted U.S. Patent Covering VX-853 to Treat Cancer Multidrug Resistance
Isis Receives Defense Department Contract For Combinatorial Antibacterial Drug Research
Vertex Pharmaceuticals and BioChem Pharma Begin Phase II Trial of Multidrug Resistance Inhibitor in Ovarian Cancer
Isis Demonstrates 'Switching' of Key Gene; Stimulates Effects of Chemotherapeutic Agents.
ComGenex and Solvo Biotech Reaches Key Milestone in a Joint Drug Discovery Program and Files Patent Application.
Isis retains significant portion of royalty stream on Macugen sales.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters